ULURU Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported revenues were $264,333,000 compared to $258,997,000 a year ago. Operating Loss was $489,117,000 compared to $701,337,000 a year ago. Loss before Income taxes were $536,243,000 compared to $729,379,000 a year ago. Net loss was $536,243,000 or $0.01 per Basic and diluted per common share compared to $729,379,000 or $0.03 per Basic and diluted per common share a year ago. The net increase of approximately $5,000 in revenues from the second quarter of 2016 compared to the second quarter of 2015 is primarily attributable to a decrease of $239,000 in Altrazeal product sales as territories in Europe and the Middle East have not generated product orders consistent with prior year and one of international distributors, Altrazeal AG, had their licensing agreement cancelled given their breach of the licensing agreement.   For the six months, the company reported revenues were $373,125,000 compared to $553,645,000 a year ago. Operating Loss was $1,068,009,000 compared to $1,334,005,000 a year ago. Loss before Income taxes were $1,182,585,000 compared to $1,467,652,000 a year ago. Net loss was $1,182,585,000 or $0.02 per Basic and diluted per common share compared to $1,467,652,000 or $0.06 per Basic and diluted per common share a year ago.  The decrease in revenues is primarily attributable to a decrease of approximately $511,000 in Altrazeal product sales as territories in Europe and the Middle East have not generated product orders consistent with prior year and one of international distributors, Altrazeal AG, had their licensing agreement cancelled by given their breach of the licensing agreement.  The decrease in Altrazeal product sales was partially offset by the recognition of unamortized licensing fees of approximately $343,000 related to the cancellation of distribution agreements with three distributors.